MarketLens
Sign Up

Why Did Gilead Pay $7.8 Billion for Arcellx

6 months ago
SHARE THIS ON:

Why Did Gilead Pay $7.8 Billion for Arcellx

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News1 week ago

Gilead Keeps Writing Bigger Checks—But Can the Drugs Keep Paying for Them?

Gilead's dividend and HIV revenue remain strong, but its enterprise relies on one blockbuster drug facing patent expiry in about a decade, raising long-term sustainability concerns.
Stock News1 months ago

Autolus Therapeutics Reports Preliminary Second Quarter 2026 Net Product Revenue and Announces Credit Facility of up to $250 Million with Perceptive Advisors

Autolus raised FY2026 AUCATZYL sales guidance to $140–150M from $120–135M after preliminary Q2 net revenue of ~$45M, and secured a $250M credit facility with $75M funded at close.
Stock News2 months ago

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for $85/share in cash, a ~$10B deal to expand into specialty endocrinology.

Breaking News

View All →

Top Headlines

View More →
Stock News1 hour ago

$10,000 in Tesla When It Joined the S&P 500 Would Be About $15,700 Today. An Index Fund Would Have Done Better.

Stock News4 hours ago

J&J Is In Talks to Sell Its Hips-and-Knees Business to Apollo for $20 Billion

Stock News5 hours ago

Google's Historic 396 MW Clean Energy Deal Just Changed the Game for 1 AI Power Play

Stock News6 hours ago

Better AI Chip Stock: Broadcom vs. Nvidia

Stock News6 hours ago

Dell Technologies Sees AI Boom Building as $95B Server Backlog Signals Demand